clinical stage drug development

AlgoTherapeutix (AlgoTx) is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a non-opioid, locally acting agent that inhibits specific nociceptive sodium channels. ATX01's lead indication is Chemotherapy-Induced Peripheral Neuropathy (CIPN), and it is in Phase 2 clinical development.

Phase 2 clinical trials

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company headquartered in San Jose, California, developing immune-based therapies to treat and prevent cancer. It has two clinical programs: an FSHR-targeted CAR-T therapy (lira-cel) for ovarian cancer in Phase 1 dose escalation, and an alpha-lactalbumin-targeted breast cancer vaccine that has completed Phase 1 and is preparing for Phase 2. Programs are developed with institutions including Cleveland Clinic, Moffitt Cancer Center, The Wistar Institute, the National Cancer Institute,

cancer vaccine developmentCAR-T cell therapy

Azevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class, orally bioavailable vasopressin V1a receptor antagonists for neuropsychiatric disorders, neurodegeneration, neurodevelopment, and brain injury. Its lead candidate SRX246 has shown Phase 2 efficacy in pathological aggression in Huntington's disease and Intermittent Explosive Disorder. The company has four clinical and preclinical programs and has raised $56M in funding.

pharmaceutical research

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function. Its nanotherapeutics target cellular energy impairments common to many diseases. It is a wholly owned subsidiary of Clene Inc.

manufacturing (Clene Manufacturing Center)nanotherapeutics development

Eluciderm is a clinical-stage regenerative medicine small-molecule pharmaceutical company based in San Diego, CA. It has developed a platform of small molecules that selectively modulate multiple Poly(ADP-ribose) polymerase (PARP) enzymes to guide tissue repair away from fibrosis and toward organized tissue regeneration. Its lead candidate ELU42 is a topical spray-on therapy in a Phase I/IIA clinical trial for diabetic foot ulcers.

regenerative medicine researchsmall-molecule PARP modulation platformtopical spray-on drug formulation

GEn1E Lifesciences is a clinical-stage, Phase 2 company accelerating first-in-class precision therapies for inflammatory and rare diseases. It discovered a new binding pocket and developed a unique, validated mechanism of action for Dual Signal Modulators targeting kinase dysregulation (p38, MK2, ERK). Its GRID AI platform supports its drug development. It received US FDA Orphan Drug and Rare Pediatric Disease designations for a dual signal modulator for Duchenne Muscular Dystrophy.

AI drug developmentkinase-targeted drug discovery

IGC Pharma is a clinical-stage biotechnology/pharmaceutical company focused on Alzheimer's disease and related dementias. Its lead candidate IGC-AD1, a partial CB1 receptor agonist with anti-inflammatory action, targets agitation in Alzheimer's dementia and has completed enrollment in the Phase 2 CALMA trial. The company also develops AI-driven predictive tools such as MINT-AD and PRISM for early Alzheimer's risk prediction and clinical decision support.

artificial intelligence predictive modelingclinical trialsmanufacturing and processingR&D

INmune Bio Inc. is a clinical stage biotechnology company focused on restoring function in the innate immune system to fight disease. Its pipeline consists of first in class therapies designed to maximize benefit without compromising safety, being developed for neurologic disease and certain forms of cancer. Drug candidates INKmune and INB03 may be used to treat cancer, while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease.

clinical trialsimmunotherapy development